Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019May 27, 2019 Alterity Therapeutics

Alterity Therapeutics AAN Presentation 5 May 2019 Download

Post navigation

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics commences US investor meetings following positive clinical data

Related Posts

Prana Provides Clinical Trials Update: Alzheimer’s and Huntington disease trials on track

July 17, 2013

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

October 18, 2016

Dr David Stamler Biotech Showcase Presentation

January 8, 2018

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting
AGM 2019 Presentation

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065